{"entity":{"id":"agonox","kind":"company","name":"AgonOx","aka":["AgonOx, Inc."],"tldr":"AgonOx is a Portland company growing a patient's own tumour-fighting immune cells for re-infusion, selecting only the fraction that recognises the tumour. Its therapy, AGX-148, is in an early trial in solid tumours.","summary":"AgonOx, Inc. develops tumour-infiltrating lymphocyte (TIL) therapy that isolates and expands the CD39-positive, CD103-positive subset of a patient's CD8 TIL, which the company describes as the tumour-reactive fraction. Its lead programme AGX-148 is in phase 1 in solid tumours, with further cell therapy programmes in IND-enabling studies. AgonOx sponsors NCT05902520, a phase 1 trial of these CD8 TIL in adults with solid tumours, which ClinicalTrials.gov lists as active and not recruiting. A 2026 National Cancer Institute SBIR award funds enriching and expanding tumour-reactive CD8 T cells to treat breast cancer.","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://www.agonox.com/"},{"label":"NIH RePORTER: award 1R44CA314796-01","url":"https://reporter.nih.gov/project-details/11408886"},{"label":"ClinicalTrials.gov: CD8 TIL in solid tumours (NCT05902520)","url":"https://clinicaltrials.gov/study/NCT05902520"}],"tags":[],"related":[],"cancers":["breast-cancer"],"sections":["cell-therapy","immunotherapy"],"technologies":["til-therapy"],"targets":[],"drugs":["agx-148"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Company website, the NIH RePORTER record and the ClinicalTrials.gov record for NCT05902520 read on 4 November 2026. NCT05902520 is not yet a trial record in OnCo."],"hq":"Portland, OR","country":"US","companyType":"cell-therapy","website":"https://www.agonox.com/","stage":"startup","investors":[],"funding":[{"round":"Grant","year":2026,"amountUsd":977639,"source":"https://reporter.nih.gov/project-details/11408886","note":"NCI SBIR (R44) award 1R44CA314796-01: Enriching and expanding tumor-reactive CD8 T-cells to treat breast cancer"}]},"route":"/companies/agonox/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"til-therapy","kind":"technology","name":"TIL therapy","route":"/technologies/til-therapy/"}],"drug":[{"id":"agx-148","kind":"drug","name":"AGX-148","route":"/drugs/agx-148/"}]}}